View Item 

Show simple item record

Molecular defects in coagulation Factor VIII and their impact on Factor VIII function

dc.contributor.authorSaenko, E. L.en_US
dc.contributor.authorAnanyeva, N.M.en_US
dc.contributor.authorKouiavskaia, D.en_US
dc.contributor.authorSchwinn, H.en_US
dc.contributor.authorJosic, D.en_US
dc.contributor.authorShima, M.en_US
dc.contributor.authorHauser, C. A. E.en_US
dc.contributor.authorPipe, Steven W.en_US
dc.date.accessioned2010-06-01T21:49:19Z
dc.date.available2010-06-01T21:49:19Z
dc.date.issued2002-08en_US
dc.identifier.citationSaenko, E. L.; Ananyeva, N.; Kouiavskaia, D.; Schwinn, H.; Josic, D.; Shima, M.; Hauser, C. A. E.; Pipe, S. (2002). "Molecular defects in coagulation Factor VIII and their impact on Factor VIII function." Vox Sanguinis 83(2): 89-96. <http://hdl.handle.net/2027.42/74861>en_US
dc.identifier.issn0042-9007en_US
dc.identifier.issn1423-0410en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74861
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12201837&dopt=citationen_US
dc.format.extent453373 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rights2002 Blackwell Science Ltden_US
dc.subject.otherConformational Changesen_US
dc.subject.otherFactor VIIIen_US
dc.subject.otherHaemophilia Aen_US
dc.subject.otherMutationsen_US
dc.subject.otherPhospholipid Bindingen_US
dc.subject.otherSurface Plasmon Resonanceen_US
dc.titleMolecular defects in coagulation Factor VIII and their impact on Factor VIII functionen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherJ. Holland Laboratory, American Red Cross, Rockville, MD, USAen_US
dc.contributor.affiliationotherGeorge Washington University, Washington, DC, USAen_US
dc.contributor.affiliationotherOctapharma AG, Lachen, Switzerlanden_US
dc.contributor.affiliationotherOctapharma Pharmazeutika, Vienna, Austriaen_US
dc.contributor.affiliationotherNara Medical University, Kashihara, Nara, Japanen_US
dc.contributor.affiliationotherDepartment of Obstetrics and Gynecology, Medical University of Lubeck, Lubeck, Germanyen_US
dc.contributor.affiliationotherOctagene Biomedical Laboratories, Martinsried, Germanyen_US
dc.identifier.pmid12201837en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74861/1/j.1423-0410.2002.00183.x.pdf
dc.identifier.doi10.1046/j.1423-0410.2002.00183.xen_US
dc.identifier.sourceVox Sanguinisen_US
dc.identifier.citedreferencevan Dieijen G, Tans G, Rosing J, Hemker HC: The role of phospholipid and factor VIII a in the activation of bovine factor X. J Biol Chem 1981; 256: 3433 – 3442en_US
dc.identifier.citedreferenceGilbert GE, Arena AA: Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-1-serine. J Biol Chem 1996; 271: 11120 – 11125en_US
dc.identifier.citedreferenceNesheim ME, Pittman DD, Wang JH, Slonosky D, Giles AR, Kaufman RJ: The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem 1988; 263: 16467 – 16470en_US
dc.identifier.citedreferenceSaenko EL, Shima M, Sarafanov AG: Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex. Trends Cardiovasc Med 1999; 9: 185 – 192en_US
dc.identifier.citedreferenceFay PJ: Regulation of Factor VIIIa in the intrinsic Factor Xase. Thromb Haemost 1999; 82: 193 – 200en_US
dc.identifier.citedreferenceMann KG: Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 165 – 174en_US
dc.identifier.citedreferenceHoyer LW: Hemophilia A. N Engl J Med 1994; 330: 38 – 47en_US
dc.identifier.citedreferenceSaenko EL, Scandella D: The acidic region of the light chain and the C2 domain together form a high affinity binding site for von Willebrand factor. J Biol Chem 1997; 272: 18007 – 18014en_US
dc.identifier.citedreferenceRegan LM, Fay PJ: Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity. J Biol Chem 1995; 270: 8546 – 8552en_US
dc.identifier.citedreferenceNogami K, Shima M, Hosokawa K, Nagata M, Koide T, Saenko E, Tanaka I, Shibata M, Yoshioka A: Factor VIII, C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg 1689. J Biol Chem 2000; 275: 25774 – 25780en_US
dc.identifier.citedreferenceNogami K, Shima M, Hosokawa K, Suzuki T, Koide T, Saenko EL, Scandella D, Shibata M, Kamisue S, Tanaka I, Yoshioka A: Role of factor VIII, C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999; 274: 31000 – 31007en_US
dc.identifier.citedreferenceSaenko EL, Scandella D, Yakhyaev AV, Greco N: Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem 1998; 273: 27918 – 27926en_US
dc.identifier.citedreferenceFoster PA, Fulcher CA, Houghten RA, Zimmerman TS: Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990; 75: 1999 – 2004en_US
dc.identifier.citedreferenceSaenko EL, Shima M, Rajalakshmi KJ, Scandella D: A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601 – 11605en_US
dc.identifier.citedreferenceHealey JF, Barrow RT, Tamim HM, Lubin IM, Shima M, Scandella D, Lollar P: Residues Glu2181–Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92: 3701 – 3709en_US
dc.identifier.citedreferencePratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL: Structure of the C2 domain of human factor VIII at 1·5 A resolution. Nature 1999; 402: 439 – 442en_US
dc.identifier.citedreferenceBarrow RT, Healey JF, Jacquemin M, Saint-Remy J-M, Lollar P: Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood 2001; 97: 169 – 174en_US
dc.identifier.citedreferenceGilbert GE, Kaufman RJ, Arena AA, Miao H, Pipe SW: Four hydrophobic amino acids of the factor VIII, C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 227: 6374 – 6381en_US
dc.identifier.citedreferenceLenting PJ, van de Loo J-WHP, Donath M-JSH, van Mourik JA, Mertens K: The sequence Glu1811–Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem 1996; 271: 1935 – 1940en_US
dc.identifier.citedreferenceFay PJ, Beattie T, Huggins CF, Regan LM: Factor VIIIa A2 subunit residues 558–565 represent a factor IXa interactive site. J Biol Chem 1994; 269: 20522 – 20527en_US
dc.identifier.citedreferenceFay PJ, Scandella D: Human inhibitor antibodies specific for the factor VIII, A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274: 29826 – 29830en_US
dc.identifier.citedreferenceFay PJ, Mastri M, Koszelak ME, Wakabayashi H: Cleavage of factor VIII heavy chain is required for the functional interaction of A2 subunit with factor IXA. J Biol Chem 2001; 276: 12434 – 12439en_US
dc.identifier.citedreferenceFay PJ, Koshibu K: The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem 1998; 273: 19049 – 19054en_US
dc.identifier.citedreferenceLollar P, Parker ET, Fay PJ: Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem 1992; 267: 23652 – 23657en_US
dc.identifier.citedreferenceFay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ: Model for the factor VIIIa-dependent decay of the intrinsic factor Xase: role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem 1996; 271: 6027 – 6032en_US
dc.identifier.citedreferenceLapan KA, Fay PJ: Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem 1997; 272: 2082 – 2088en_US
dc.identifier.citedreferenceLapan KA, Fay PJ: Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking. Thromb Haemost 1998; 80: 418 – 422en_US
dc.identifier.citedreferenceSaenko EL, Shima M, Gilbert GE, Scandella D: Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996; 271: 27424 – 27431en_US
dc.identifier.citedreferenceGilbert GE, Drinkwater D, Barter S, Clouse SB: Specificity of phosphatidylserine-containing membrane binding sites for factor VIII. Studies with model membranes supported by glass microspheres (liposheres). J Biol Chem 1992; 267: 15861 – 15868en_US
dc.identifier.citedreferenceSaenko E, Sarafanov A, Ananyeva N, Behre E, Shima M, Schwinn H, Josic D: Comparison of the properties of phospholipid surfaces formed on HPA and L1 biosensor chips for the binding of the coagulation factor VIII. J Chromatogr A 2001; 921: 49 – 56en_US
dc.identifier.citedreferenceRaut S, Di Giambattista M, Bevan SA, Hubbard AR, Barrowcliffe T, Laub R: Modification of factor VIII in therapeutic concentrates after virus inactivation by virus inactivation by solvent–detergent and pasteurisation. Thromb Haemost 1998; 80: 624 – 631en_US
dc.identifier.citedreferenceRaut S, Weller L, Barrowcliffe T: Phospholipid binding of factor VIII in different therapeutic concentrates. Br J Haematol 1999; 107: 323 – 329en_US
dc.identifier.citedreferenceSaenko E, Josic D, Stadler M, Sarafanov A, Lim Y-P, Shima M, Ananyeva N, Schwinn H: Molecular modifications in factor VIII concentrates produced from different plasma pools. Thromb Res 2001; 101: 501 – 511en_US
dc.identifier.citedreferenceLaub R, Di Giambattista M, Fondu P, Brackmann H-H, Lenk H, Saenko E, Felch M, Scandella D: Inhibitors in German Hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of fVIII light chain. Thromb Haemost 1999; 81: 39 – 44en_US
dc.identifier.citedreferenceSawamoto Y, Prescott R, Zhong D, Saenko E, Mauser-Bunschoten E, Peerlinck K, van den Berg M, Scandella D: Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost 1998; 79: 62 – 68en_US
dc.identifier.citedreferenceSaenko EL, Scandella D: A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem 1995; 270: 13826 – 13833en_US
dc.identifier.citedreferenceSandberg H, Almstedt A, Brandt J, Gray E, Holmquist L, Oswaldsson U, Sebring S, Mikaelsson M: Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001; 85: 93 – 100en_US
dc.identifier.citedreferenceShima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H: A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240 – 246en_US
dc.identifier.citedreferenceScandella D, Gilbert GE, Shima M, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Saenko E: Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248–2312 which overlap a phospholipid binding site. Blood 1995; 86: 1811 – 1819en_US
dc.identifier.citedreferencePock K, Rizzi A, Josic D: Use of high-resolution techniques for the characterization of clotting factor VIII. J Chromatogr A 1999; 852: 175 – 188en_US
dc.identifier.citedreferencePock K, Jungbauer A, Kannicht C, Loster K, Buchacher A, Josic D: Electrophoretic analyses of clotting factor VIII concentrates. Anal Chim Acta 1998; 372: 219 – 229en_US
dc.identifier.citedreferenceSandberg H, Almstedt A, Brandt J, Castro VM, Gray E, Holmquist L, Lewin M, Oswaldsson U, Mikaelsson M, Jankowski MA, Bond M, Scoble HA: Structural and functional characterization of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 4 – 12en_US
dc.identifier.citedreferenceAshton RW, Scheraga HA: Preparation and characterization of anhydrothrombin. Biochemistry 1995; 34: 6454 – 6463en_US
dc.identifier.citedreferenceHill-Eubanks DC, Parker CG, Lollar P: Differential proteolytic activation of factor VIII–von Willebrand factor complex by thrombin. Proc Natl Acad Sci USA 1989; 86: 6508 – 6512en_US
dc.identifier.citedreferenceHill-Eubanks DC, Lollar P: von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem 1990; 265: 17854 – 17858en_US
dc.identifier.citedreferenceArai M, Inaba H, Higuchi M, Antonarakis SE, Kazazian HH Jr, Fujimaki M, Hoyer LW: Direct characterization of factor VIII in plasma: detection of a mutation altering a thrombin cleavage site (arginine-372 histidine). Proc Natl Acad Sci USA 1989; 86: 4277 – 4281en_US
dc.identifier.citedreferenceShima M, Ware J, Yoshioka A, Fukui H, Fulcher CA: An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule. Blood 1989; 74: 1612 – 1617en_US
dc.identifier.citedreferenceAcquila M, Caprino D, Pecorara M, Baudo F, Morfini M, Mori PG: Two novel mutations at 373 codon of FVIII gene detected by DGGE. Thromb Haemost 1993; 69: 392 – 393en_US
dc.identifier.citedreferenceSchwaab R, Oldenburg J, Lalloz MR, Schwaab U, Pemberton S, Hanfland P, Brackmann HH, Tuddenham EG, Michaelides K: Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein. Hum Genet 1997; 101: 323 – 332en_US
dc.identifier.citedreferenceGitschier J, Kogan S, Levinson B, Tuddenham EGD: Mutations of factor VIII cleavage sites in hemophilia A. Blood 1988; 72: 1022 – 1028en_US
dc.identifier.citedreferenceSchwaab R, Ludwig M, Kochhan L, Oldenburg J, McVey JH, Egli H, Brackmann HH, Olek K: Detection and characterisation of two missense mutations at a cleavage site in the factor VIII light chain. Thromb Res 1991; 61: 225 – 234en_US
dc.identifier.citedreferenceKamisue S, Shima M, Nishimura T, Tanaka I, Nakai H, Morichika S, Takata N, Kuramoto A, Yoshioka A: Abnormal factor VIII Hiroshima: defect in crucial proteolytic cleavage by thrombin at arg 1689 detected by a novel ELISA. Br J Haemotol 1994; 86: 106 – 111en_US
dc.identifier.citedreferenceDuncan EM, Duncan BM, Tunbridge LJ, Lloyd JV: Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 1994; 87: 846 – 848en_US
dc.identifier.citedreferenceKeeling DM, Sukhu K, Kemball-Cook G, Waseem N, Bagnall R, Lloyd JV: Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954→Leu substitution in the factor VIII, A3 domain. Br J Haematol 1999; 105: 1123 – 1126en_US
dc.identifier.citedreferenceBarrowcliffe TW: Methodology of the two-stage assay of Factor VIII (VIII:C). Scand J Haematol Suppl 1984; 41: 25 – 38en_US
dc.identifier.citedreferenceStoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A: 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron microscopy. Blood 2002; 99: 1 – 7en_US
dc.identifier.citedreferencePemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EGD, Kemball-Cook G: A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413 – 2421en_US
dc.identifier.citedreferencePipe SW, Saenko E, Kaufman RJ: Mild hemophilia A caused by increased rate of factor VIII, A2 subunit dissociation: evidence for non-proteolytic inactivation of factor VIII in vivo. Blood 1999; 93: 176 – 183en_US
dc.identifier.citedreferencePipe SW, Saenko EL, Eickhorst AN, Kemball-Cook G, Kaufman RJ: Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein–protein interactions within the triplicated A domains of thrombin-activated factor VIIIa. Blood 2001; 97: 685 – 691en_US
dc.identifier.citedreferenceShima M, Matsumoto T, Fukuda K, Kubota Y, Tanaka I, Nishiya K, Giles AR, Yoshioka A: The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of Haemophilia A patients with very low levels of Factor VIII activity (FVIII:C). Thromb Haemost 2002; 87: 436 – 441en_US
dc.identifier.citedreferencePipe SW, Kaufman RJ: Factor VIII, C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J Biol Chem 1996; 271: 26571 – 25676en_US
dc.identifier.citedreferenceNesbitt IM, Hinks JL, Sampson B, Kitchen S, Peake IR, Makris M, Goodeve AC: Discrepant one- and two-stage fVIII assays are very common in mild haemophilia A: correlation with fVIII gene mutations. Thromb Haemost 2001; ( Suppl. July ) OC195en_US
dc.identifier.citedreferenceHakeos WH, Pipe SW, Saenko EL, Kaufman RJ: Hemophilia A mutations within the factor VIII, A2–A3 subunit interface destabilize fVIIIa and cause one-stage/two-stage activity discrepancy. Blood 2001; 96: 532aen_US
dc.identifier.citedreferenceDavid D, Saenko EL, Santos IM, Johnson DJ, Tuddenham EG, McVey JH, Kemball-Cook G: Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRM(–)) and G1948D (CRM(r)). Br J Haematol 2001; 113: 604en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1423-0410.2002.00183.x.pdf
Size:
442.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.